Combined treatment of HPV-positive HNSCC cells with Xevinapant, Tuvusertib and ionizing radiation
Laryngo-Rhino-Otologie · 01.05.2024 · 103 (S 02 S 02) · S235-S236
DOI: 10.1055/s-0044-1784772 ↗Kurz gefasst
Fachartikel in der Zeitschrift Laryngo-Rhino-Otologie, erschienen am 01.05.2024. Verfasst von Julius Röhrle und 8 weiteren Autor:innen.
Abstract (Originalsprache)
Combined treatment of HPV-positive HNSCC cells with Xevinapant, Tuvusertib and ionizing radiation
Zitieren
APA
Röhrle, J., Zech, H., Gatzemeier, F., Christiansen, S., Wahrhausen, N., Petersen, C., Betz, C., Rothkamm, K., & Rieckmann, T. (2024). Combined treatment of HPV-positive HNSCC cells with Xevinapant, Tuvusertib and ionizing radiation. Laryngo-Rhino-Otologie, 103(S 02 S 02), S235-S236. https://doi.org/10.1055/s-0044-1784772
Vancouver
Röhrle J, Zech H, Gatzemeier F, Christiansen S, Wahrhausen N, Petersen C, et al. Combined treatment of HPV-positive HNSCC cells with Xevinapant, Tuvusertib and ionizing radiation. Laryngo-Rhino-Otologie. 2024;103(S 02 S 02):S235-S236. doi:10.1055/s-0044-1784772
BibTeX
@article{Rhrle2024,
author = {Röhrle, Julius and Zech, Henrike and Gatzemeier, Fruszina and Christiansen, Sabrina and Wahrhausen, Nanik and Petersen, Cordula and Betz, Christian and Rothkamm, Kai and Rieckmann, Thorsten},
title = {Combined treatment of HPV-positive HNSCC cells with Xevinapant, Tuvusertib and ionizing radiation},
journal = {Laryngo-Rhino-Otologie},
year = {2024},
volume = {103},
number = {S 02 S 02},
pages = {S235--S236},
doi = {10.1055/s-0044-1784772}
}
EUVIMED